Application	AMENDMENT TRANSMITTAL LETTER					
	Application No.		Filing Date			Art Unit 1648
10/091,567-Conf. #7851		March 7, 2002		Myron G. Hi	<u> </u>	1048
olicant(s): Jona	than P. WON	3 et al				
ention: DNA VA	ACCINE USING	S LIPOSOME- ROTEIN OF IN	ENCAPSULA FLUENZA VI	ATED PLASMID DI RUS	NA ENCO	DING FOR
	TC	THE COMMI	SSIONER FO	R PATENTS		
ansmitted herev						
ne fee has been	calculated and			The second secon		
	A.		S AS AMEN	DED	1	
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate		
Total Claims	10	- 20 =	0	×		0.00
Independent Claims	4	- 3 =	1	86		86.00
Multiple Depend	ent Claims (ch	eck if applicabl	θ)			ĵ
Other fee (please specify): Petition for Extension of Time						110.00
TOTAL ADDITIONAL FEE FOR THIS AMENDMENT:						196.00
X Please charge A duplicate of A check in the Payment by X The Commiss as described X Credit as X Charge as Robert S. Gree Attorney Reg. N	copy of this sho ne amount of \$ credit card. For ssioner is here to below. A dup ny overpayment any additional file on	count No. eet is enclosed form PTO-2038 by authorized folicate copy of ant. ing or application	to cover is attached. to charge and this sheet is	the amount of \$ the filing fee is end credit Deposit Accendosed. fees required under	closed.	18-0013 16 and 1.17.

#17/C

Docket No.: NEL-0006 (80283-0014)

PATENT APPLICATION

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Jonathan P. WONG et al.

Confirmation No.: 7851

Application No.: 10/091,567

Art Unit: 1648

Filed: March 7, 2002

Examiner: Myron G. Hill

For: NEL-006 DNA VACCINE USING

LIPOSOME-ENCAPSULATED PLASMID DNA ENCODING FOR HEMAGGLUTININ

PROTEIN OF INFLUENZA VIRUS

AMENDMENT

MS RCE Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the final Office Action dated June 3, 2003 (Paper No. 11), finally rejecting claims 8-13, 18 and 19, and prior to Continued Examination pursuant to a Request Fro Continued Examination submitted concurrently herewith, please amend the above-identified U.S. patent application as follows:

Amendments to the Claims are reflected in the listing of claims which begins on page 3 of this paper.

Remarks/Arguments begin on page 5 of this paper.